For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

Opportunities in the GLP-1 receptor agonist market include the development of new diabetes and obesity treatments with high ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

Adults with overweight or obesity regained most weight lost during GLP-1 receptor agonist treatment at 1 year following cessation.

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

Twenty percent of potentially eligible youth are prescribed GLP-1 RAs, with the odds of prescription higher with increasing ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss appear to be similarly effective among adults across ages, races, and starting weights, according to a review published online ...

The findings of this cohort study suggest that glucagon-like peptide–1 receptor agonist (GLP-1 RA) use was associated with significant reduction in all-cause mortality among patients with cancer with ...

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Less than 25 percent of adults with overweight or obesity without diabetes remain on any glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment after 12 months, according to a research letter ...

GLP-1 RAs are prescribed to about 20% of potentially eligible adolescents, with increasing odds based on several individual factors.

From 2023, there was a decrease in use of metabolic and bariatric surgery, with stronger decline for sleeve gastrectomy.